Overview

Comparison of Three Liraglutide Formulations in Healthy Volunteers

Status:
Completed
Trial end date:
2005-03-30
Target enrollment:
Participant gender:
Summary
This trial is conducted in Oceania. The aim of this trial is to test for bioequivalence between each of the two new liraglutide formulations at pH 7.9 and 8.15 and the planned Phase 3 formulation at pH 7.7.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Liraglutide